Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating alnuctamab versus standard-of-care regimens in relapsed or refractory multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Alnuctamab

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 3 | Status: WITHDRAWN